blood disorders

View All

Hemophilia A Market Forecast and Assessment
Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape

Hemophilia A treatment scenario before the launch of HEMLIBRA Despite the ups and downs throughout history, the management of hemophilia A patients substantially improved over the past 40 years. The groundbreaking discovery of cryoprecipitate in 1964 marked the beginning of the modern progression of hemophilia t...

Find More

Biogen’s Aduhelm; FDA Approves Sanofi’s Enjaymo; NHS & Orchard Signs a Deal; Bristol’s Breyanzi & Abecma; Pharming’s Leniolisib; Eli Lilly’s Verzenio Trial; UCB’ Zilucoplan Trials Result; Eli Lilly’s Alzheimer’s Drug Donanemab

Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limited sales and a constraining Medicare coverage plan, the medicine is now facing additional scrutiny as part of a pair...

Find More

Beta Thalassemia Pharmacological Therapies
Beta-Thalassemia Pharmacological Therapies

Thalassemia is a group of inherited blood disorders that are a result of defects or mutations in the genes. The defect results in defective or less production of the haemoglobin, thus hampering the transport of the oxygen to all the body parts. The most common form of the thalassemia is Beta-Thalassemia. It cau...

Find More